

Resource Summary Report

Generated by [NIF](#) on Aug 13, 2026

B6.Cg-Foxn1^{nu}/J

RRID:IMSR_JAX:000819

Type: Organism

Proper Citation

RRID:IMSR_JAX:000819

Organism Information

URL: <https://www.jax.org/strain/000819>

Proper Citation: RRID:IMSR_JAX:000819

Description: Mus musculus with name B6.Cg-Foxn1^{nu}/J from IMSR.

Species: Mus musculus

Synonyms: B6 nude. Foxn1. C57BL/6 nude

Notes: gene symbol note: forkhead box N1; mutant strain|congenic strain: Foxn1

Affected Gene: forkhead box N1

Genomic Alteration: nude

Catalog Number: JAX:000819

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: B6.Cg-Foxn1^{nu}/J

Record Creation Time: 20250513T053621+0000

Record Last Update: 20260808T050823+0000

Ratings and Alerts

No rating or validation information has been found for B6.Cg-Foxn1^{nu}/J.

No alerts have been found for B6.Cg-Foxn1^{nu}/J.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 165 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Liu R, et al. (2026) Lung Adenocarcinoma Promotes NETosis via the NPM1-TNFAIP6-CD44-SPP1 Axis. *Cancers*, 18(6).

Moloney C, et al. (2026) Intraoperative drug delivery to hindbrain tumours via an injectable hydrogel is well tolerated and confers survival benefit against atypical teratoid/rhabdoid xenografts. *Drug delivery and translational research*, 16(7), 2456.

Cheng T, et al. (2026) m6A Methyltransferase METTL3 Regulates Inflammatory and Immune Microenvironments in Renal Cell Carcinoma via Modulation of the PI3K/AKT Pathway. *International journal of genomics*, 2026, 4975062.

Formenti L, et al. (2026) Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer. *Journal of experimental & clinical cancer research : CR*, 45(1), 45.

Li Y, et al. (2026) Clathrin mediated endocytosis targeting chimera for targeted membrane proteins degradation and enhance CAR-T cell anti-tumor therapy. *Theranostics*, 16(1), 254.

Vega AG, et al. (2026) A Computational Model of Tumor Interactions with Bone-Resident Cells Predicts Tumor-Type-Specific Responses to Perturbations. *bioRxiv : the preprint server for biology*.

Wu H, et al. (2026) Transplantation of Soluble Epoxide Hydrolase Inhibitor-Treated Human Brown Adipocytes Promotes Adipose Tissue Activation in High-Fat-Diet-Fed Nude Mice. *International journal of molecular sciences*, 27(3).

Loughran RM, et al. (2026) Noncanonical PI(4,5)P2 coordinates lysosome positioning through cholesterol trafficking. *Science advances*, 12(21), eaeb8658.

Burchett R, et al. (2026) A Universal Boosting Strategy for Adoptive T-cell Therapy Using a Paired Vaccine/Chimeric Antigen Receptor. *Cancer immunology research*, 14(2), 261.

Tian P, et al. (2025) Breast cancer induces CD62L+ Kupffer cells via DMBT1 to promote neutrophil extracellular trap formation and liver metastasis. *Cell discovery*, 11(1), 68.

Li H, et al. (2025) Neuron-like macrophage differentiation via the APOE-TREM2 axis contributes to chronic pain in nasopharyngeal carcinoma. *Cell biology and toxicology*, 41(1), 86.

Sun S, et al. (2025) KSHV reprograms host RNA splicing via FAM50A to activate STAT3 and drive oncogenic cellular transformation. *mBio*, 16(7), e0129325.

Oka T, et al. (2025) T helper 2 cell-directed immunotherapy eliminates precancerous skin lesions. *The Journal of clinical investigation*, 135(1).

Westerman BA, et al. (2025) Challenges to determine synergistic drug interactions in mice. *Nature communications*, 16(1), 8533.

Zhu Y, et al. (2025) Folate metabolism-associated CYP26A1 is a clinico-immune target in colorectal cancer. *Genes and immunity*, 26(4), 376.

Gonzalez J, et al. (2025) A Conserved Di-Lysine Motif in the E2 Transactivation Domain Regulates MmuPV1 Replication and Disease Progression. *Pathogens (Basel, Switzerland)*, 14(1).

Wang X, et al. (2025) Inhibition of Histone Deacetylases Induces Cancer Cell Apoptosis Through the PERK Pathway of ER Stress Response. *Journal of cellular and molecular medicine*, 29(21), e70928.

Ko HM, et al. (2025) Liprin-??1 enhances PHLDB3 oncogenic function in colorectal cancer via activation of mTORC2-AKT1 pathway. *Cell reports*, 45(1), 116722.

Veo B, et al. (2025) Single-cell multi-omics identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma. *Nature communications*, 16(1), 10470.

Elayapillai SP, et al. (2025) Oklahoma nitron-007 is an effective anticancer therapeutic agent targeting inflammatory and immune metabolism pathways in endometrial cancer. *The Journal of pharmacology and experimental therapeutics*, 392(1), 100004.